I could be argued that it would make most sense, if NNZ-2591 has successful results in all 4 current indications, for a well-resourced pharma to run concurrent Phase 3 trials. But from a risk-managing perspective, that might not be an attractive option for them.
Also, outside of those 4 indications, where does Acadia stand with NNZ-2591 in Rett and Fragile-X? Phase 2 or 3 trials are yet to be held and so are quite some years away from any FDA approval. Why would Acadia bother if, say, NNZ-2591 in PMS was approved in a few years’ time, setting off the ticking of the IRA clock on Acadia's in-licensed NNZ-2591 Rett and Fragile-X assets?
What does make sense to me is for Neuren to continue to proceed full steam ahead on Phase 3 in PMS as that just continues to add value. I think the big decision-making point wouldn’t come until the time of any NDA submission and, in the meantime, the IRA law might have been amended and/or Neuren might have already been acquired and it’s someone else’s decision to make!
- Forums
- ASX - By Stock
- NEU
- Ann: Trading Halt
Ann: Trading Halt, page-96
-
- There are more pages in this discussion • 136 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$13.16 |
Change
0.220(1.70%) |
Mkt cap ! $1.682B |
Open | High | Low | Value | Volume |
$13.23 | $13.35 | $13.02 | $2.828M | 214.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 417 | $13.15 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.17 | 997 | 13 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
17 | 791 | 13.170 |
4 | 783 | 13.160 |
10 | 1161 | 13.150 |
3 | 560 | 13.140 |
5 | 947 | 13.130 |
Price($) | Vol. | No. |
---|---|---|
13.190 | 236 | 5 |
13.200 | 929 | 6 |
13.210 | 785 | 8 |
13.220 | 1017 | 9 |
13.230 | 1047 | 7 |
Last trade - 13.45pm 14/10/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |